AEON Biopharma, Inc.
AEON· NYSE
Released Aug 12, 2024, after the close
10-Q filed Aug 12, 2024, 43 days after period end · 0001558370-24-011896
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Net Income | $164.11M | -$15.38M | $1.87M | -$4.03M |
| EPS Diluted | $304.00 | -$0.11 | — | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
AEON Biopharma, Inc. · CIK 1837607 · Engraved from SEC EDGAR